Medical Management for NIHSS 18 Acute Ischemic Stroke
For a patient with NIHSS 18 and acute ischemic infarct, IV alteplase (0.9 mg/kg, max 90 mg) should be administered immediately if within 4.5 hours of symptom onset, followed by urgent evaluation for mechanical thrombectomy if a large vessel occlusion is present. 1
Immediate Reperfusion Strategy
IV Thrombolysis (First-Line)
Administer IV alteplase as quickly as possible if the patient presents within the therapeutic window 1:
- 0-3 hours from onset: Class I indication regardless of stroke severity. Despite increased hemorrhagic transformation risk with severe strokes (NIHSS 18 qualifies as severe), proven clinical benefit exists 1
- 3-4.5 hours from onset: Class I indication if patient meets criteria (age ≤80, no diabetes + prior stroke combination, NIHSS ≤25, not on oral anticoagulants) 1
Dosing: 0.9 mg/kg (maximum 90 mg) over 60 minutes, with 10% given as bolus over 1 minute 1
Critical eligibility requirements 1:
- Blood pressure controllable to <185/110 mmHg
- Glucose >50 mg/dL
- No intracranial hemorrhage on CT
- Time last known normal is clearly <3 or <4.5 hours
Mechanical Thrombectomy Evaluation
Immediately obtain vascular imaging (CTA or MRA) to identify large vessel occlusion 2. With NIHSS 18, there is high probability (>85%) of proximal vessel occlusion in anterior circulation 3.
Proceed with mechanical thrombectomy if:
- Large vessel occlusion confirmed (ICA, M1, or proximal M2)
- Can be performed within 6 hours of onset (or extended windows with advanced imaging)
- This is Class I recommendation and should be pursued even if alteplase was given 2
Post-Thrombolysis Management
Intensive Monitoring Protocol 1
Neurological and blood pressure monitoring:
- Every 15 minutes during and for 2 hours after alteplase infusion
- Every 30 minutes for next 6 hours
- Hourly until 24 hours post-treatment
Blood pressure targets 1:
- Maintain ≤180/105 mmHg during and for 24 hours after treatment
- If BP >180/105 mmHg, increase monitoring frequency and treat aggressively
- After successful thrombectomy with reperfusion, consider maintaining <180/105 mmHg (Class IIa) 1
Discontinue alteplase immediately if: severe headache, acute hypertension, nausea/vomiting, or neurological worsening occurs—obtain emergency head CT 1
Antiplatelet Therapy Timing
Delay aspirin for 24 hours after IV alteplase 1. The standard recommendation is:
- Aspirin 160-300 mg should be started 24-48 hours after stroke onset 1
- Earlier administration (<24 hours post-alteplase) carries uncertain hemorrhage risk, though one retrospective study showed no increased bleeding 1
- Exception: May consider earlier if compelling indication exists where withholding aspirin poses substantial risk 1
Do not use aspirin as substitute for acute reperfusion therapy in otherwise eligible patients 1
Critical Pitfalls to Avoid
Time delays: Every minute matters—"door-to-needle" time should be ≤60 minutes, ideally ≤45 minutes 1. Do not delay alteplase for additional imaging beyond non-contrast CT if within 3-hour window
Premature prognostication: Avoid early discussions of poor outcome. NIHSS 18 is severe but does not preclude meaningful recovery, especially with successful reperfusion 4, 5
Missing large vessel occlusion: NIHSS ≥9 within 3 hours has 86.4% positive predictive value for vessel occlusion 3. Failure to pursue thrombectomy evaluation is a critical error
Invasive procedures: Delay nasogastric tubes, Foley catheters, and arterial lines for 24 hours unless absolutely necessary 1
Premature anticoagulation/antiplatelet therapy: Wait 24 hours and obtain follow-up imaging before starting these agents 1
Follow-up Imaging
Obtain CT or MRI at 24 hours before initiating anticoagulants or antiplatelet agents 1. This identifies hemorrhagic transformation and guides subsequent antithrombotic therapy.
Key Nuance on Severity
The 2018 AHA/ASA guidelines explicitly state that severe stroke symptoms are a Class I indication for IV alteplase within 3 hours, acknowledging increased hemorrhagic risk but emphasizing proven clinical benefit 1. NIHSS 18 falls well within this severe category. The ECASS-III trial excluded NIHSS >25 for the 3-4.5 hour window, but subsequent analysis suggests this exclusion may not be justified in practice 1.